Thomas Marron, PhD, MD, discusses the end points of an exploratory study which examines the use of cemiplimab in hepatocellular carcinoma.
Thomas Marron, MD
Articles by Thomas Marron, MD
Thomas Marron, MD, discusses the rationale for investigating immunotherapy discontinuation in patients with melanoma.
Latest Updated Articles
Study of Cemiplimab Use in Hepatocellular Carcinoma Meets Primary End PointsPublished: February 26th 2022 | Updated:
Timing of Immunotherapy Discontinuation Remains Challenging in MelanomaPublished: November 20th 2019 | Updated: